Overview

* AnaptysBio ( ANAB ) Q3 collaboration revenue rises significantly due to GSK milestone achievements

* Company plans to separate biopharma operations from royalty assets by YE 2026

* AnaptysBio ( ANAB ) reports Q3 net income, contrasting with a loss in the prior year

Outlook

* AnaptysBio ( ANAB ) plans to separate biopharma operations from royalty assets by YE 2026

* Company expects $75 mln milestone from GSK's Jemperli sales in Q4 2025

* AnaptysBio ( ANAB ) expects annualized Jemperli royalties of >$390 mln before 2031

Result Drivers

* GSK MILESTONE - Collaboration revenue boosted by $50 mln milestone from GSK's Jemperli sales exceeding $750 mln

* BIOPHARMA SEPARATION - Intent to separate biopharma operations from royalty assets by YE 2026 to unlock value

* ROSNILIMAB DATA - Positive Phase 2b data for rosnilimab in rheumatoid arthritis highlighted at ACR Convergence 2025

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $76.32

Collabor mln

ation

Revenue

Q3 Net $15.11

Income mln

Q3 $34.70

Income mln

From

Operatio

ns

Q3 $41.61

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for AnaptysBio Inc ( ANAB ) is $62.00, about 41.9% above its November 3 closing price of $36.04

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)